Ratio: tuning the pharmacokinetics of radiotherapies
The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies
Ratio is developing small molecule radiotherapies it believes thread the needle between maximizing tumor exposure and minimizing off-target effects. The company emerged from stealth in June 2022, and raised a $20 million series A round led by Duquesne Capital and Schusterman Family Investments in February.
Co-founder, President and CSO John Babich told BioCentury that Ratio Therapeutics Inc. is a sequel company to Noria Therapeutics Inc., which was founded in 2017 to develop the targeted radiotherapy and diagnostic technology he co-invented as an academic at Weill Cornell Medicine. ...